ArticleMolecular neurobiology2025
Leucine-Rich Repeat Kinase 2 Relates to Neuroaxonal Degeneration via Tau Pathology and Microglial Activation in Alzheimer's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Leucine-rich repeat kinase 2 (LRRK2), a key contributor to Parkinson's disease (PD). However, its potential role in Alzheimer's disease (AD) progression remains unclear. This study analyzed baseline and 5-year follow-up data from 716 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 87 participants in the Parkinson's Progression Markers Initiative (PPMI). Participants had cerebrospinal fluid (CSF) LRRK2 or LRRK2 (rs34637584 and rs76904798) genotypes, CSF biomarkers for AD core pathology, microglial activation and synaptic function, and underwent cognitive assessments. The mean age was 72.62 ± 7.34 years for the ADNI and 62.32 ± 9.66 years for the PPMI. The associations between LRRK2 and AD biomarkers were tested in CN, MCI and AD groups. In both ADNI and PPMI, CSF LRRK2 levels were correlated with CSF P-tau, T-tau, NfL, and α-syn. In ADNI, CSF LRRK2 showed correlations with sTREM2, PGRN, TREM2, TREML2, TRML1.ITIM, and Ng. Longitudinally, CSF LRRK2 was only correlated with the MOCA score in PPMI. Across CN, MCI, and AD groups, CSF LRRK2 levels exhibited correlations with sTREM2, PGRN, TREM2, TREML2, TREML1.ITIM, and NfL. The association between CSF LRRK2 and T-tau and P-tau was most pronounced in the MCI stage. Conversely, no significant association was observed between CSF LRRK2 and Aβ
Indexed as
Identifiers
41351686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.